The Supreme Court declined to hear Teva's challenge to a $235 million award to GlaxoSmithKline in a patent dispute over generic drugs involving heart medication Coreg, according to a Reuters report.

The use of low-dose carvedilol did not significantly improve certain cardiac measures of heart failure risk in long-term survivors of childhood cancer exposed to anthracycline compared with placebo, ...

As the biopharma industry seeks clarity on so-called "skinny" labels, the United States’ top lawyer is calling on the Supreme Court to take up the long-running feud between Teva and GSK. In a 29-page ...

WASHINGTON (Reuters) - GlaxoSmithKline Plc said on Friday it won U.S. approval to sell a new once- a-day formulation of its Coreg hypertension drug. The new version, Coreg CR, is designed to be ...

As promised back in February, Teva Pharmaceuticals has asked the U.S. Supreme Court to overturn its $235 million loss in the company’s long-running “skinny label” patent feud with GSK. The case, which ...

Maximum plasma concentrations of carvedilol occur 1-2 hours after oral administration. [9] Absolute bioavailability of carvedilol is approximately 23% due to extensive first-pass metabolism. [9] Food ...

A new court ruling has the future use of skinny labels in question, but skinny-label generics have saved Medicare a lot of money over 5 years. Skinny labels, which carve out patent-protected ...